Wisconsin Discovery Portal

Researcher: Douglas McNeel

[ printable ]
Areas of Expertise
  • Hematology
  • Oncology
  • Genitourinary cancer
  • Internal medicine
Web Site Douglas McNeel's Department of Medicine Website
Curriculum Vitae (CV)
Issued Patent(s)
  • 9,339,538 - Bystander immune suppression as a predictor for response to a vaccine, issued May 2016.
  • 9,060,961 - Molecules and methods for treatment and detection of cancer, issued June 2015.
  • 8,962,590 - Prostate cancer vaccine, issued February 2015.
  • 8,603,485 - Bystander immune suppression as a predictor for response to a vaccine, issued December 2013.
  • 8,513,210 - Prostate cancer vaccine, issued August 2013.
USPTO Published Applications
  • 20160166686 - Mini-intronic plasmid dna vaccines in combination with lag3 blockade, published June 2016.
  • 20160129098 - Targeting dna vaccines to b cells as primary antigen presenting cells, published May 2016.
  • 20150306197 - Prostate cancer vaccine, published October 2015.
  • 20140161818 - Bystander immune suppression as a predictor for response to a vaccine, published June 2014.
  • 20140105853 - Prostate cancer vaccine, published April 2014.
Recent Publication(s)
  • SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Bloom JE, McNeel DG. Oncotarget. 2016 Jun 2. doi: 10.18632/oncotarget.9802. [Epub ahead of print]

  • Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Clin Cancer Res. 2016 May 11. pii: clincanres.2839.2015. [Epub ahead of print]

  • Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Hum Vaccin Immunother. 2015;11(10):2469-74. doi: 10.1080/21645515.2015.1062190.

  • PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3.


View Douglas McNeel's publications at PubMed.
Recent Artistic Works
Collaboration
  • St Lukes Hospital, Milwaukee, WI
Research Tools
Research Facilities
E-mail Address [email protected]
Phone Number 608-263-4198
Current University UW–Madison
Department Medicine
Title Professor
Other Appointments
Address Line 1 7007 Wisconsin Institutes for Medical Research
Address Line 2 1111 Highland Avenue
City Madison
State WI
Zip Code 53705
Bachelor's Degree B.A., Whitman College, Chemistry & Music, 1986
Master's Degree
PhD Ph.D., University of Chicago, 1992
Other Degrees M.D., University of Chicago, 1994
Technologies Available for Licensing Methods and Compositions for Treating Prostate Cancer with DNA Vaccines

Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines

Prostate Cancer and Melanoma Screening